Mutation prevalence and delays in obtaining results between the genetics referral cohort and the gynecologic oncologist-initiated testing cohort
| Genetics referral cohort (January 2014–July 2017) | Gynecologic oncologist-initiated genetic testing (August 2017–August 2018) | Significance | |
| Patients with HGSC | 108 | 44 | |
| Patients undergoing genetic testing, n (%) | 54 (50%) | 38 (86.3%) | |
| Prevalence of germline BRCA mutations, n (%) | 14 (25.9%) | 8 (21.1%) | |
| BRCA1 | 5 (9.2%) | 5 (13.1%) | |
| BRCA2 | 9 (16.7%) | 3 (7.8%) | |
| Median time from diagnosis to genetics consult | 53 days (range 3–751 days) | ||
| Median time from diagnosis to genetic testing | 154 days (range 4–848 days) | 40 days (range 8–175 days) | P<0.01 |
| Median delay between testing and result | 28.5 days (range 7–271 days) | 8 days (range 8–48 days) | P=0.002 |
| Median time from diagnosis to result | 58 days (range 19–175 days) | P<0.01 |
186 days (range 15–938 days)
P-values obtained with the Mann–Whitney U test for medians
*HGSC :high-grade serous ovarian, tubal, or peritoneal carcinoma, BRCA: BReast CAncer gene